Invesco Ltd. Buys New Shares in Takeda Pharmaceutical Co. $TAK

Invesco Ltd. bought a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 49,947 shares of the company’s stock, valued at approximately $743,000.

Several other institutional investors have also added to or reduced their stakes in TAK. Charles Schwab Investment Management Inc. raised its stake in Takeda Pharmaceutical by 22.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 311,216 shares of the company’s stock worth $4,628,000 after buying an additional 57,665 shares in the last quarter. Lester Murray Antman dba SimplyRich grew its stake in shares of Takeda Pharmaceutical by 76.2% in the first quarter. Lester Murray Antman dba SimplyRich now owns 34,671 shares of the company’s stock worth $515,000 after acquiring an additional 14,999 shares during the period. ABC Arbitrage SA bought a new stake in Takeda Pharmaceutical during the first quarter valued at approximately $4,994,000. Jefferies Financial Group Inc. bought a new stake in Takeda Pharmaceutical during the first quarter valued at approximately $199,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Takeda Pharmaceutical during the first quarter valued at approximately $205,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Ratings Changes

Separately, Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold”.

Takeda Pharmaceutical Trading Down 0.1%

TAK stock opened at $15.15 on Thursday. The firm’s fifty day simple moving average is $14.82 and its two-hundred day simple moving average is $14.76. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $48.19 billion, a price-to-earnings ratio of 50.48 and a beta of 0.22. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.56.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.